AR065014A1 - Derivado de heterocicliden-n-(aril)acetamida - Google Patents

Derivado de heterocicliden-n-(aril)acetamida

Info

Publication number
AR065014A1
AR065014A1 ARP080100291A ARP080100291A AR065014A1 AR 065014 A1 AR065014 A1 AR 065014A1 AR P080100291 A ARP080100291 A AR P080100291A AR P080100291 A ARP080100291 A AR P080100291A AR 065014 A1 AR065014 A1 AR 065014A1
Authority
AR
Argentina
Prior art keywords
group
compound
salt
solvate
isomer
Prior art date
Application number
ARP080100291A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR065014A1 publication Critical patent/AR065014A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a un compuesto, representado por la formula (1): (en donde m, n, y p cada uno representa 0 hasta 2; q representa 0 o 1; k representa halogeno, un grupo hidrocarburo, un grupo heterocíclico, un grupo alcoxi, un grupo alcoxicarbonilo, un grupo sulfamoilo, un grupo CN, o un grupo NO2 o similares; R2 representa halogeno, amino, un grupo hidrocarburo, un grupo heterocíclico aromático, o un grupo oxo; X1 representa O, -NR3- o - S(O)r-; Q' representa un grupo heteroarilo, un grupo heteroarilalquilo, un grupo arilo sustituido, o un grupo aralquilo; la porcion Ciclo representa un anillo heteroarilo o un anillo arilo; y la línea punteada representa un isomero-E o un isomero-Z), una sal del compuesto, o un solvato del compuesto o la sal. Una composicion farmacéutica y un antagonista del receptor del tipo I potencial del receptor temporal (TRF) cada uno contiene, como un ingrediente activo, al menos un compuesto, una sal del compuesto, y un solvato del compuesto o la sal.
ARP080100291A 2007-01-24 2008-01-24 Derivado de heterocicliden-n-(aril)acetamida AR065014A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007014372 2007-01-24

Publications (1)

Publication Number Publication Date
AR065014A1 true AR065014A1 (es) 2009-05-13

Family

ID=39644589

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100291A AR065014A1 (es) 2007-01-24 2008-01-24 Derivado de heterocicliden-n-(aril)acetamida

Country Status (14)

Country Link
EP (1) EP2128157A4 (es)
JP (1) JPWO2008091021A1 (es)
KR (1) KR20090107068A (es)
CN (1) CN101589038A (es)
AR (1) AR065014A1 (es)
AU (1) AU2008208224A1 (es)
CA (1) CA2676020A1 (es)
CL (1) CL2008000202A1 (es)
CO (1) CO6210825A2 (es)
MX (1) MX2009007954A (es)
PA (1) PA8766901A1 (es)
PE (1) PE20081692A1 (es)
TW (1) TW200902002A (es)
WO (1) WO2008091021A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101136183B1 (ko) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 신규 헤테로시클리덴 아세트아미드 유도체
NZ571706A (en) * 2006-04-18 2012-06-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2011201776A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
AU2009269720A1 (en) 2008-06-17 2012-01-19 Glenmark Pharmaceuticals S.A. Chromane derivatives as TRPV3 modulators
JP2011201778A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
JP2011201777A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
UY33966A (es) 2011-03-25 2012-10-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
EP4410989A2 (en) * 2019-08-23 2024-08-07 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivatives
US20220324790A1 (en) * 2019-09-12 2022-10-13 BASF Agro B.V. Process for the preparation of a-methyl-[4-(nitro)-2-(trifluoromethyl) -benzyl nitrate
KR102334947B1 (ko) * 2020-04-22 2021-12-06 주식회사 제이맥켐 Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309621D0 (en) 1993-05-11 1993-06-23 Wellcome Found Amide derivatives and their therapeutic use
EP0716083A4 (en) 1993-08-26 1996-08-28 Yamanouchi Pharma Co Ltd BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES THEREOF
DE19620170A1 (de) 1996-05-20 1997-11-27 Wolfgang Prof Dr Dr Pfleiderer Nucleosid-Derivate mit photolabilen Schutzgruppen
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
WO2001036381A1 (fr) 1999-11-15 2001-05-25 Nissan Chemical Industries, Ltd. Composes hydrazone et pesticides
US6120964A (en) 1999-12-15 2000-09-19 Eastman Kodak Company 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers
ES2327620T3 (es) 2001-11-16 2009-11-02 Astellas Pharma Inc. Derivado de 4,4-difluoro-1,2,3,4-tetraidro-5h-1-benzacepina o sales del mismo.
CA2468544A1 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
TW200403223A (en) * 2002-02-15 2004-03-01 Glaxo Group Ltd Novel compounds
MXPA04011579A (es) * 2002-05-29 2005-03-07 Amgen Inc Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular.
AU2003299797A1 (en) 2002-12-19 2004-07-14 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
US20040192728A1 (en) 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
RU2333198C2 (ru) 2003-06-12 2008-09-10 Астеллас Фарма Инк. Производные бензамида или фармацевтически приемлемые соли указанного производного, фармацевтическая композиция на их основе и применение
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1664041B1 (en) 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
TW200526631A (en) 2003-10-07 2005-08-16 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005044802A2 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives as vrl antagonists
US7553848B2 (en) 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005095329A1 (en) 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
RU2392278C2 (ru) 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
WO2006038871A1 (en) 2004-10-08 2006-04-13 Astrazeneca Ab New hydroxymethylbenzothiazoles amides
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
JP2007014372A (ja) 2005-07-05 2007-01-25 Kariya Mokuzai Kogyo Kk 椅子
KR101136183B1 (ko) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 신규 헤테로시클리덴 아세트아미드 유도체

Also Published As

Publication number Publication date
CN101589038A (zh) 2009-11-25
JPWO2008091021A1 (ja) 2010-05-20
CL2008000202A1 (es) 2009-10-02
PA8766901A1 (es) 2009-06-23
KR20090107068A (ko) 2009-10-12
AU2008208224A1 (en) 2008-07-31
CA2676020A1 (en) 2008-07-31
EP2128157A1 (en) 2009-12-02
EP2128157A4 (en) 2010-03-17
WO2008091021A1 (ja) 2008-07-31
MX2009007954A (es) 2009-08-07
TW200902002A (en) 2009-01-16
PE20081692A1 (es) 2008-12-18
CO6210825A2 (es) 2010-10-20

Similar Documents

Publication Publication Date Title
AR065014A1 (es) Derivado de heterocicliden-n-(aril)acetamida
ECSP088129A (es) Derivado novedoso de heterocicliden acetamida
PH12016501813B1 (en) 1,3-benzodioxole derivative
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
CO6382126A2 (es) Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
AR057661A1 (es) Un derivado de oxima y sus preparaciones
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
AR064521A1 (es) Activador de glucoquinasa
TW200738596A (en) Benzamide and heteroarene derivatives
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
ECSP11011318A (es) Derivados de benzofurano
GEP20146014B (en) Heterocyclic sulfonamides, usage thereof and their pharmaceutical compositions
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
AR065280A1 (es) Agentes antiparasitarios
MX2010004293A (es) Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet.
BR112015009798A2 (pt) compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
EA200700584A1 (ru) Непептидные антагонисты брадикинина и фармацевтические композиции на их основе
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
EA201201082A1 (ru) Фармацевтическая композиция, содержащая n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal